D. AblashiL. ChatlynneH. CooperD. ThomasM. YadavA. W. NorhanomA. K. ChandanaV. ChurdboonchartS. A.R. KulpradistM. PatnaikK. LiegmannR. MasoodM. ReitzF. CleghornA. MannsP. H. LevineC. RabkinR. BiggarF. JensenP. GillN. JackJ. EdwardsJ. WhitmanC. BoshoffAdvanced Biotechnologies Inc.University of MalayaMahidol UniversitySpecialty LaboratoriesUniversity of Southern CaliforniaUniversity of Maryland, BaltimoreNational Cancer InstituteGeorge Washington University School of Medicine and Health SciencesOrchestra Therapeutics IncMed. Res. Found. of Trinidad and T.Chester Beatty Research Institute2018-09-072018-09-071999-11-09British Journal of Cancer. Vol.81, No.5 (1999), 893-897000709202-s2.0-0032718747https://repository.li.mahidol.ac.th/handle/123456789/25326Seroprevalence of HHV-8 has been studied in Malaysia, India, Sri Lanka, Thailand, Trinidad, Jamaica and the USA, in both healthy individuals and those infected with HIV. Seroprevalence was found to be low in these countries in both the healthy and the HIV-infected populations. This correlates with the fact that hardly any AIDS-related Kaposi's sarcoma has been reported in these countries. In contrast, the African countries of Ghana, Uganda and Zambia showed high seroprevalences in both healthy and HIV-infected populations. This suggests that human herpes virus-8 (HHV-8) may be either a recently introduced virus or one that has extremely low infectivity. Nasopharyngeal and oral carcinoma patients from Malaysia, Hong Kong and Sri Lanka who have very high EBV titres show that only 3/82 (3.7%) have antibody to HHV-8, demonstrating that there is little, if any, cross-reactivity between antibodies to these two gamma viruses.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1038/sj.bjc.6690782